Urokinase Plasminogen Activator and Its Receptor in Pancreatic Cancer
Author Information
Author(s): D Cantero, H Friess, J Deflorin, A Zimmermann, M-A Brundler, E Riesle, M Korc, M W Buchler
Primary Institution: University of Bern, Inselspital, Bern, Switzerland; University of California Irvine, California, USA
Hypothesis
The study investigates the role of urokinase plasminogen activator (uPA) and its receptor (uPAR) in pancreatic cancer and their potential as prognostic markers.
Conclusion
The overexpression of uPA and uPAR in pancreatic cancer is associated with shorter post-operative survival, suggesting they may serve as prognostic markers.
Supporting Evidence
- Immunohistochemical analysis showed moderate to strong immunostaining of uPA and uPAR in most pancreatic cancers.
- Patients with concomitant overexpression of uPA and uPAR had a median post-operative survival of 9 months.
- Normal pancreatic tissues showed low levels of uPA and uPAR mRNA, while pancreatic cancer samples showed a sixfold and fourfold increase in uPA and uPAR mRNA levels, respectively.
Takeaway
This study found that two proteins, uPA and uPAR, are found in higher amounts in pancreatic cancer, and having more of them means patients might not live as long after surgery.
Methodology
The study used immunohistochemistry and Northern blot analysis to assess uPA and uPAR expression in pancreatic cancer tissues.
Participant Demographics
30 patients with pancreatic cancer (12 female, 18 male; median age 66.5 years) and 30 normal controls (14 women, 16 men; median age 41 years).
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website